[The kinetics of rhodamine 123 efflux from cells with multiple drug resistance under the action of energy metabolism inhibitors].
A study was made of the effects of inhibitors of ATP synthesis on the process of rhodamine 123 (R-123) release from sensitive sp2/0-Ag14 cells, multidrug-resistant mouse myeloma spEBR-5 cells and hybridoma IF7, derived from spEBR-5 cells. It has been shown that IF7 cells are cross-resistant to ethidium bromide, colchicine, actinomycin D and adriamycin. However, hybridoma IF7 cells, compared to parental spEBR-5 cells, show a lower resistance index. When studying the dependence of the R-123 efflux rate on glycolysis intensity (effect of 2 mM 2-deoxyglucose) and on the level of oxidative phosphorylation activity (effect of 2 mM KCN and 30 microM dinitrophenol), the following distinctive properties of the R-123 transport system of IF7 cells (compared to spEBR-5 cells) were detected: 1) uptake of R-123 into IF7 cells is similar to that observed for the sensitive sp2/0-Ag14 cells; 2) efflux of R-123 from IF7 cells takes place more intensely; 3) R-123 transport is dependent on the rate of glycolysis and may be inhibited by KCN. It is found that 2,4-dinitrophenol inhibits the R-123 efflux from all the cells. Verapamil reverses the multidrug resistance both in spEBR-5 and IF7 cells. The mechanisms of multidrug resistance of cells are discussed.
Gamaleĭ
I A
IA
Berezkina
E V
EV
Kovaleva
Z V
ZV
Ignatova
T N
TN
D000255:Adenosine Triphosphate / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D000818:Animals; D003864:Depression, Chemical; D018432:Drug Resistance, Multiple / Q000502:physiology*; D004734:Energy Metabolism / Q000187:drug effects*; D005434:Flow Cytometry / Q000379:methods; D006019:Glycolysis / Q000187:drug effects; D006825:Hybridomas / Q000378:metabolism; D051379:Mice; D009101:Multiple Myeloma / Q000378:metabolism; D012235:Rhodamines / Q000493:pharmacokinetics*; D014407:Tumor Cells, Cultured
D012235:Rhodamines; D000255:Adenosine Triphosphate
Kinetika vykhoda rodamina 123 iz kletok s mnozhestvennoĭ lekarstvennoĭ ustoĭchivost'iu pri deĭstvii ingibitorov énergeticheskogo metabolizma.